Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bimosiamose

Next Previous
Drug Profile

Bimosiamose

Alternative Names: BIMO; Bimosiamose disodium; TBC 1269; TBC 1269z

Latest Information Update: 20 Aug 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Encysive Pharmaceuticals
  • Developer Revotar Biopharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics; Glycoconjugates; Hexanes; Skin disorder therapies; Small molecules
  • Mechanism of Action E-selectin inhibitors; L-selectin inhibitors; P selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lung injury
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute lung injury; Adult respiratory distress syndrome; Asthma; Chronic obstructive pulmonary disease; Plaque psoriasis

Most Recent Events

  • 28 Sep 2011 Final efficacy & adverse events data from a phase II trial in Chronic obstructive pulmonary disease presented at the 21st Annual Congress of the European Respiratory Society (ERS-2011)
  • 30 Mar 2011 Discontinued - Phase-I for Adult respiratory distress syndrome in Germany (Inhalation)
  • 30 Mar 2011 Discontinued - Phase-II for Plaque psoriasis in Germany (Intradermal)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top